Reuters logo
BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence
2016年10月6日 / 下午12点47分 / 1 年前

BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence

Oct 6 (Reuters) - Orexo AB :

* U.S. FDA approves Orexo’s low dose zubsolv buprenorphine and naloxone sublingual tablets (CIII)

* Orexo U.S. says U.S. FDA has approved Zubsolv 0.7mg/0.18mg for treatment of patients with opioid dependence Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below